Drugs that contain Pralsetinib
1. List of Gavreto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10030005 | GENENTECH INC | Inhibitors of RET |
Nov, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273160 | GENENTECH INC | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 4, 2025 |
| Orphan Drug Exclusivity (ODE) | Sep 4, 2027 |
NCE-1 date: 2024-09-04
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy
Dosage: CAPSULE;ORAL
GAVRETO family patents
19
United States
6
Japan
3
China
3
Israel
3
European Union
2
Singapore
2
Brazil
2
Korea, Republic of
2
Canada
2
Chile
2
Australia
1
Russia
1
Costa Rica
1
Philippines
1
Mexico
1
Argentina
1
Morocco
1
Peru
1
Taiwan, Province of China
1
Hong Kong
1
EA
1
South Africa
1
Saudi Arabia
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic